Abstract: The invention relates to peptides of the formula IR.sup.4 -A.sup.5 -A.sup.6 -A.sup.7 (I)in which R.sup.4 denotes an acyl group, R.sup.5 denotes D-Lys or Lys, A.sup.6 denotes the radical of phenylalanine, N-methylphenylalanine, 4-alkoxyphenylalanine or 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, and R.sup.7 denotes a basic radical, processes for their preparation and their use.

Abstract: Oxindole compounds of the formula I ##STR1## in which R.sup.1, R.sup.2, R.sup.3, R.sup.1', R.sup.2', R.sup.3', R.sup.4, R.sup.5 and R.sup.6 have the meanings given, and physiologically acceptable salts thereof, for the treatment of epilepsy and their use for the preparation of a medicament for the treatment of epilepsy are described.

Abstract: The invention relates to peptides of the formula IR.sup.4 --A.sup.5 --A.sup.6 --A.sup.7 (I)in which R.sup.4 denotes an acyl group, R.sup.5 denotes D-Lys or Lys, A.sup.6 denotes the radical of phenylalanine, N-methylphenylalanine, 4- alkoxyphenylalanine or 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, and R.sup.7 denotes a basic radical, processes for their preparation and their use.

Abstract: Oxindole derivatives of the general formula I ##STR1## are described, and also processes for their preparation and drugs containing them. The new compounds exhibit a neuroanabolic action in various animal models.

Abstract: New isoquinoline derivatives of the general formula ##STR1## and their physiologically acceptable salts, which exert pharmacological actions on the central nervous system and the heart circulation system, a process for the preparation of these compounds, medicaments containing them, and their use as neuroleptic, antihypertonic and antiarrhythmic agents, are described.

Abstract: 1-Phenylisoquinoline derivatives of the general formula I ##STR1## and a process for their preparation are described. They act on the central nervous system, in particular as antidepressants.

Abstract: Oxindole derivatives of the general formula I ##STR1## are described, and also processes for their preparation and drugs containing them. The new compounds exhibit a neuroanabolic action in various animal models.

Abstract: Isoquinolines of the formula ##STR1## of which representative compounds are such as 3-N-methylpiperazino-1-phenyl-isoquinoline-4-aldehyde, 3-N-methylpiperazino-1-(2-fluorophenyl)-isoquinoline-4-aldehyde, or 3-N-[3-(4-fluoro-benzoyl)-propyl]-piperazino-1-phenyl-isoquinoline-4-aldeh yde and medicaments containing the isoquinolines which are useful as antidepressants.

Abstract: Isoquinoline-4-aldehydes of the formula ##STR1## in which X denotes bromine or chlorine, R.sub.1 is phenyl optionally mono- or disubstituted by halogen, hydroxy, nitro, amino, or amino substituted by one or two aliphatic, cycloaliphatic or aromatic hydrocarbon radicals having from 2 to 18 carbon atoms, the nitrogen atom possibly being included in a heterocyclic ring, acyl amino, alkyl or alkoxy each having from 1 to 6 carbon atoms, benzoyloxy, or trifluoromethyl, or is pyridyl or thienyl;R.sub.2 is hydrogen, halogen, hydroxy, alkyl or alkoxy having from 1 to 6 carbon atoms, nitro, amino, benzyloxy, methylene dioxy or ethylene dioxy andm is 1 or 2;which are effective in the treatment of spasms and as tranquilizers.

Abstract: Pharmaceutical preparations containing an L-pyroglutamic acid amide, processes for their preparation and methods of treating psychotic diseases with them.

Abstract: The invention relates to tripeptide amides containing pyroglutamine, proline and histidine as amino acids having anti-depressive activity and a process for their manufacture.